Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CG Oncology, Inc. stock logo
CGON
CG Oncology
$26.03
-3.2%
$26.10
$14.80
$40.47
$1.98B0.86875,411 shs1.49 million shs
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
$21.99
+0.8%
$20.91
$13.45
$44.42
$1.93B0.03987,550 shs672,746 shs
Lionheart Acquisition Co. II stock logo
LCAP
Lionheart Acquisition Co. II
$27.06
+0.4%
$10.38
$8.94
$11.70
$499.30M0.08102,067 shs9,331 shs
PACS Group, Inc. stock logo
PACS
PACS Group
$11.51
-1.0%
$11.53
$8.28
$43.92
$1.75B0.92810,011 shs389,473 shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CG Oncology, Inc. stock logo
CGON
CG Oncology
+0.56%+3.86%+5.28%+31.35%-23.62%
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
+1.02%-3.41%+0.65%+17.07%-46.66%
Lionheart Acquisition Co. II stock logo
LCAP
Lionheart Acquisition Co. II
0.00%+0.34%+3.94%+17.67%+5,291.78%
PACS Group, Inc. stock logo
PACS
PACS Group
-2.97%-10.07%-12.27%+33.70%-64.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CG Oncology, Inc. stock logo
CGON
CG Oncology
2.4973 of 5 stars
4.51.00.00.02.40.80.0
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
4.2377 of 5 stars
4.41.00.04.42.81.70.0
Lionheart Acquisition Co. II stock logo
LCAP
Lionheart Acquisition Co. II
N/AN/AN/AN/AN/AN/AN/AN/A
PACS Group, Inc. stock logo
PACS
PACS Group
2.8543 of 5 stars
3.41.00.00.02.20.01.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CG Oncology, Inc. stock logo
CGON
CG Oncology
3.08
Buy$55.30112.47% Upside
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
2.86
Moderate Buy$47.55116.17% Upside
Lionheart Acquisition Co. II stock logo
LCAP
Lionheart Acquisition Co. II
0.00
N/AN/AN/A
PACS Group, Inc. stock logo
PACS
PACS Group
2.86
Moderate Buy$34.29197.90% Upside

Current Analyst Ratings Breakdown

Latest LCAP, IDYA, CGON, and PACS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/22/2025
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy
7/16/2025
CG Oncology, Inc. stock logo
CGON
CG Oncology
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$68.00 ➝ $53.00
7/10/2025
CG Oncology, Inc. stock logo
CGON
CG Oncology
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$40.00
7/10/2025
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold$25.00
7/9/2025
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeOutperform ➝ Moderate Buy$57.00 ➝ $30.00
6/26/2025
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$44.00
6/26/2025
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$44.00
6/17/2025
CG Oncology, Inc. stock logo
CGON
CG Oncology
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$52.00 ➝ $56.00
5/22/2025
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$63.00 ➝ $66.00
5/19/2025
CG Oncology, Inc. stock logo
CGON
CG Oncology
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$55.00 ➝ $52.00
5/2/2025
CG Oncology, Inc. stock logo
CGON
CG Oncology
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$41.00
(Data available from 7/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CG Oncology, Inc. stock logo
CGON
CG Oncology
$1.14M1,740.16N/AN/A$9.63 per share2.70
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
$7M275.18N/AN/A$12.25 per share1.80
Lionheart Acquisition Co. II stock logo
LCAP
Lionheart Acquisition Co. II
N/AN/A$1.31 per share20.64($2.85) per shareN/A
PACS Group, Inc. stock logo
PACS
PACS Group
$3.11B0.56N/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CG Oncology, Inc. stock logo
CGON
CG Oncology
-$88.04M-$1.51N/AN/AN/A-15,945.17%-16.71%-16.24%8/14/2025 (Estimated)
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
-$274.48M-$3.59N/AN/AN/AN/A-29.28%-27.68%8/5/2025 (Estimated)
Lionheart Acquisition Co. II stock logo
LCAP
Lionheart Acquisition Co. II
$3.21MN/A0.00N/AN/A-44.30%1.39%N/A
PACS Group, Inc. stock logo
PACS
PACS Group
$112.87MN/A0.006.47N/AN/AN/AN/A8/11/2025 (Estimated)

Latest LCAP, IDYA, CGON, and PACS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
CG Oncology, Inc. stock logo
CGON
CG Oncology
-$0.49N/AN/AN/AN/AN/A
8/11/2025Q3 2024
PACS Group, Inc. stock logo
PACS
PACS Group
$0.45N/AN/AN/AN/AN/A
8/5/2025Q2 2025
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
-$0.85N/AN/AN/A$3.48 millionN/A
5/13/2025Q1 2025
CG Oncology, Inc. stock logo
CGON
CG Oncology
-$0.36-$0.45-$0.09-$0.45$0.53 million$0.05 million
5/6/2025Q1 2025
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
-$0.75-$0.82-$0.07-$0.82$2.10 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CG Oncology, Inc. stock logo
CGON
CG Oncology
N/AN/AN/AN/AN/A
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
N/AN/AN/AN/AN/A
Lionheart Acquisition Co. II stock logo
LCAP
Lionheart Acquisition Co. II
N/AN/AN/AN/AN/A
PACS Group, Inc. stock logo
PACS
PACS Group
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CG Oncology, Inc. stock logo
CGON
CG Oncology
N/A
30.97
30.97
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
N/A
13.92
13.92
Lionheart Acquisition Co. II stock logo
LCAP
Lionheart Acquisition Co. II
N/A
0.05
0.05
PACS Group, Inc. stock logo
PACS
PACS Group
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
CG Oncology, Inc. stock logo
CGON
CG Oncology
26.56%
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
98.29%
Lionheart Acquisition Co. II stock logo
LCAP
Lionheart Acquisition Co. II
N/A
PACS Group, Inc. stock logo
PACS
PACS Group
N/A

Insider Ownership

CompanyInsider Ownership
CG Oncology, Inc. stock logo
CGON
CG Oncology
N/A
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
2.50%
Lionheart Acquisition Co. II stock logo
LCAP
Lionheart Acquisition Co. II
19.40%
PACS Group, Inc. stock logo
PACS
PACS Group
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
CG Oncology, Inc. stock logo
CGON
CG Oncology
6176.22 millionN/AOptionable
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
8087.58 million85.39 millionOptionable
Lionheart Acquisition Co. II stock logo
LCAP
Lionheart Acquisition Co. II
318.45 million14.87 millionNot Optionable
PACS Group, Inc. stock logo
PACS
PACS Group
32,433152.40 millionN/AOptionable

Recent News About These Companies

New anti-Mamdani PAC looks to raise $25M
Northern Ireland engineering group sold to investor

New MarketBeat Followers Over Time

Media Sentiment Over Time

CG Oncology stock logo

CG Oncology NASDAQ:CGON

$26.03 -0.87 (-3.25%)
As of 03:57 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

IDEAYA Biosciences stock logo

IDEAYA Biosciences NASDAQ:IDYA

$21.99 +0.18 (+0.84%)
As of 03:57 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Lionheart Acquisition Co. II stock logo

Lionheart Acquisition Co. II NASDAQ:LCAP

Lionheart Acquisition Corporation II does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in PropTech sector. The company was incorporated in 2019 and is based in Miami, Florida.

PACS Group stock logo

PACS Group NYSE:PACS

$11.51 -0.11 (-0.96%)
As of 03:57 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

PACS Group, Inc., through its subsidiaries, operates skilled nursing facilities and assisted living facilities in the United States. The company also provides senior care and independent facilities. It engages in the acquisition, ownership, and leasing of health care-related properties. The company was founded in 2013 and is based in Farmington, Utah.